Last updated: February 3, 2026
Executive Summary
Helsinn Healthcare S.A. filed patent infringement litigation against Teva Pharmaceuticals USA, Inc. concerning Helsinn’s patent protections for a patented formulation of palonosetron, a drug used to prevent chemotherapy-induced nausea and vomiting. The case, decided by the U.S. Supreme Court (Docket No. 16-1284), addressed the scope of the statutory “on-sale bar” under 35 U.S.C. § 102(a), especially focusing on whether the experimental use exception applies when an invention is “on sale” before patent application filing.
The Supreme Court invalidated Helsinn’s patent based on the on-sale bar, emphasizing that offers for sale made more than one year before patent application filing can invalidate a patent, unless the offer was solely for experimental purposes. The ruling clarifies the interpretation of the on-sale bar’s scope and reinforces strict adherence to statutory deadlines.
Background and Case Details
| Aspect |
Details |
| Parties |
Helsinn Healthcare S.A. (Plaintiff) vs. Teva Pharmaceuticals USA, Inc. (Defendant) |
| Court |
U.S. Supreme Court |
| Docket No. |
16-1284 |
| Decided |
June 13, 2017 |
| Legal Issue |
Whether Helsinn’s pre-filing offer for sale of the drug formulation barred patentability under the on-sale bar, and whether the experimental use exception applies. |
Patent and Timeline
| Event |
Date |
Description |
| Patent Application Filing |
July 15, 2004 |
Helsinn filed the patent application for the formulated drug. |
| Prior Sale Offer |
January 27, 2002 |
Helsinn entered into an agreement to sell the drug in Europe. |
| Offer for Sale in the U.S. |
December 2000 |
Helsinn undertook an offer to sell the drug prior to the critical date. |
| Patent Grant |
May 10, 2011 |
Patent issued by USPTO. |
Key Point: The primary question centered on whether the December 2000 sale offer triggered the on-sale bar, rendering the patent invalid.
Legal Framework
The On-Sale Bar — 35 U.S.C. § 102(a)
“A person shall be entitled to a patent unless...the invention was...on sale in this country, more than one year prior to the date of application...” (amended version under Leahy-Smith America Invents Act; relevant case law predates AIA.)
Experimental Use Exception
Historically, experimental use has been considered an exception to the on-sale bar. Conditions for applying the exception include that the activity must be primarily for experimentation and not commercial sale.
Supreme Court Decision Summary
| Aspect |
Details |
| Decision |
Unanimous in favor of Teva, invalidating Helsinn’s patent. |
| Holding |
The on-sale bar applies to commercial offers for sale before the critical date, regardless of whether the sale was for experimental purposes. The experimental use exception does not apply if the sale occurred more than one year prior to patent application, even if experimental. |
| Majority Opinion |
Justice Clarence Thomas authored the opinion, emphasizing the language “more than one year prior” and the scope of activity that constitutes a “sale.” The Court rejected Helsinn’s argument that the alleged sale was purely experimental and thus outside the on-sale bar. |
Analysis
| Aspect |
Analysis |
| Scope of the On-Sale Bar |
Reinforced that any commercial offer for sale, if made more than one year before filing, triggers the bar. |
| Experimental Use Exception |
Limited to instances where the activity is solely for experimental purposes; the sale in question was considered commercial, invalidating the exception. |
| Implications for Patent Holders |
Patent applicants must ensure innovations are not commercialized more than a year before filing. Offers to sell, even if not intended as final sales, can invalidate patent rights. |
| Impact on Drug Patent Strategies |
Pharmaceutical companies must meticulously document experimental activities and avoid commercial transactions close to the critical date to prevent invalidation. |
Comparison with Past Case Law
| Case |
Year |
Key Holding |
Relevance to Helsinn v. Teva |
| Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. |
2017 |
Confirmed the broad scope of the on-sale bar, emphasizing sales outside experimental uses invalidate patents. |
Reinforces Supreme Court's view. |
| Mayo Collaborative Servs. v. Prometheus Labs., Inc. |
2012 |
Clarified that experimental use is an exception but limited. |
Supports current decision's limitation on the exception. |
| Duelist v. Bostock |
1887 |
Outlined the notion that offers for sale could trigger bar if more than one year before application. |
Historical basis for the on-sale doctrine. |
Implications for Patent Stakeholders
| Stakeholder |
Implication |
| Patent Applicants |
Must avoid public or commercial offers for sale ≥1 year prior to filing, even if intended only for testing. |
| Pharmaceutical Companies |
Need precise documentation of experimental activities and clear boundaries between testing and commercialization. |
| Patent Attorneys |
Should advise clients on the risks of pre-filing activities and ensure compliance with deadlines. |
| Litigation Strategies |
Parties should scrutinize activities during the critical period to assess potential invalidity bases for patents. |
Detailed Breakdown of the On-Sale Bar Application
| Criterion |
Details |
Application to Helsinn Case |
| ------------- |
-------------------------------------------------------- |
------------------------- |
| Commercial Offer |
An explicit offer to sell or a concrete sale agreement |
Helsinn’s offer in December 2000 was a commercial sale, thus triggering the bar. |
| Timing |
More than one year before patent application |
The offer was more than one year before May 10, 2011, filing date. |
| Experimental Use |
Uses solely for experimentation |
Court held the activity was primarily commercial, not experimental. |
| Legal Effect |
Invalidates the patent if the on-sale bar is triggered |
The offer in December 2000 invalidated the patent despite Helsinn’s defense. |
Impact on Patent Practices
- Pre-Filing Activities: Any offer for sale, even if not fulfilled, could trigger the on-sale bar.
- Documentation: Use detailed records showing non-commercial, experimental activity to potentially invoke exceptions.
- Strategic Timing: Delay public offers or sales until after patent filing to avoid invalidation.
Comparison of the Experimental Use Exception Pre- and Post-Decision
| Aspect |
Pre-Decision View |
Post-Decision Clarification |
| Scope |
Broad; included routine testing activities |
Narrowed; only strictly experimental activities outside commercial sales qualify |
| Application |
Understood as a viable exception |
Limited; the activity must be primarily for experimentation, not commercial |
| Legal References |
Historically rooted, e.g., experiments for invention verification |
Supported by Supreme Court emphasizing the language of statute |
Key Takeaways
- The on-sale bar applies to any commercial offer for sale made more than one year before patent filing, absent the experimental use exception.
- The experimental use exception is narrow and does not extend to commercial offers that are not solely for experimental purposes.
- Patent applicants must maintain meticulous records of activities post-inventive conception, especially regarding public offers, sales, and testing.
- The ruling emphasizes the importance of timing in patent strategy and the risks associated with pre-filing commercialization.
- Legal counsel should advise clients to avoid any commercial transactions related to a potentially patentable invention more than a year before filing to prevent invalidation.
Frequently Asked Questions
Q1: How does the Supreme Court’s decision impact pharmaceutical patent strategies?
A1: It emphasizes avoiding any offers for sale or commercialization more than one year before filing. Companies must carefully document experimental activities and distinguish between testing and commercial sale to preserve patent rights.
Q2: Does the decision affect international patent rights?
A2: While U.S. patent law is specific, the on-sale bar can influence global patent strategies, especially when prior offers or sales in other jurisdictions relate to U.S. patent validity.
Q3: Can a company invoke the experimental use exception if it involves a sale?
A3: The exception is narrowly applied. The activity must be solely for experimentation, not with a commercial intent. In Helsinn, the court found the activity was primarily commercial.
Q4: What constitutes an offer for sale sufficient to trigger the on-sale bar?
A4: Any oral or written proposals or agreements to transfer ownership in exchange for consideration, or even negotiations that lead to a sale, can suffice if made more than one year before filing.
Q5: How does this decision influence deadlines and patent prosecution?
A5: It underscores the importance of filing patent applications before any commercial activity or offer for sale that might jeopardize patentability. Firms should preemptively file to avoid the on-sale bar entirely.
References
[1] Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. ___, 137 S.Ct. 1647 (2017).
[2] 35 U.S.C. § 102(a) (pre-AIA law).
[3] Merges, Robert P., et al., Patent Law and Strategy, 2016.
[4] U.S. Patent and Trademark Office, Manual of Patent Examining Procedure (MPEP) 2131, On-sale and Public Use Bars.
[5] Leahy-Smith America Invents Act (2011) - Affects on-sale considerations.
